Response letter regarding the letter to the editors by Brown et al.

References

• Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012 Oct; 12(10):781-9; PMID:22920953; http://dx.doi.org/10.1016/S1473-3099(12)70187-1. Epub 2012 Aug 22.
   PubMed Web of Science ®Google Scholar
• GSK Clinical Study Register. Study of the efficacy of candidate HPV 16/18 VLP vaccine in the prevention of HPV-16 and/or HPV-18 cervical infection in adolescent & young adult women in North America and Brazil vaccinated in primary study 580299/001. Available from: http://www.gsk-clinicalstudyregister.com/study/580299/007?study_ids=580299/007#ps. Updated 2011 Oct 27; accessed 2015 Sep 1. GSK Study ID 580299/007.
   Google Scholar
• GSK Clinical Study Register. Follow-up study to evaluate the long-term efficacy of a HPV vaccine (580299) in healthy young adult women in Brazil. In: GSK Clinical Study Register [Internet]. Available from: http://www.gsk-clinicalstudyregister.com/study/109616%20%28Y7%29#rs. Updated 2014 Nov 20; accessed 2015 Sep 1. GSK Clinical Study Register Identifier: 109616 (Y7).
   Google Scholar
• Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J, Romanowski B, Roteli-Martins C, Burlet N, Mihalyi A and Frank Struyf. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Exp Rev Vacc 15(3):367-387. http://dx.doi.org/10.1586/14760584.2016.1124763. Epub 2016 Feb 22.
   Google Scholar
• Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015 Jul; 16(7):775-86; PMID:26071347; http://dx.doi.org/10.1016/S1470-2045(15)00047-9; Epub 2015 Jun 9
   PubMed Web of Science ®Google Scholar
• Moscicki A-B, Harper D, Naud P, Wheeler C, Blatter M, De Carvalho N, Ferris D, Roteli-Martins C, Teixeira J, Tyring S et al. HPV-16/18 AS04-adjuvanted vaccine: sustained immunogenicity against HPV-31 and HPV-45 non-vaccine oncogenic types up to 9.4 years follow-up [Abstract HPV15-0620]. In Proceedings of the International Papillomavirus Society - 30th International Papillomavirus Conference. Lisbon, Portugal: 2015 Sep 17-21.
   Google Scholar
• GSK Clinical Study Register. A study to evaluate safety, immunogenicity and efficacy of GSK Biologicals HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above. Available from: http://www.gsk-clinicalstudyregister.com/study/104820#rs. Updated 2015 Dec 7; accessed 2015 Dec 7. GSK Clinical Study Register Identifier: 104820.
   Google Scholar
• Skinner SR, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RH, Quek SC, da Silva DP, et al. Efficacy, safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in women over 25 years: 4-year interim follow-up of the double-blind, randomised VIVIANE study. Lancet 2014 Dec 20; 384(9961):2213-27; http://dx.doi.org/10.1016/S0140-6736(14)60920-X. Epub 2014 Sep 1
   PubMed Web of Science ®Google Scholar
• Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, Ahmed S, Palmer T, Pollock KG. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009-2013. Emerg Infect Dis 2016 Jan; 22(1):56-64; PMID:26692336; http://dx.doi.org/10.3201/eid2201.150736
   PubMed Web of Science ®Google Scholar
• Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015 Feb 19;372(8):711-23; PMID: 25693011; http://dx.doi.org/10.1056/NEJMoa1405044
   PubMed Web of Science ®Google Scholar
• Di Mario S, Basevi V, Lopalco PL, Balduzzi S, D'Amico R, Magrini N. Are the two human papillomavirus vaccines really similar? A systematic review of available evidence: efficacy of the two vaccines against HPV. J Immunol Res 2015; 2015:435141. doi: 10.1155/2015/435141. Epub 2015 Aug 25. Review. PubMed PMID: 26380321; PubMed Central PMCID: PMC4562171.
   PubMed Web of Science ®Google Scholar
• Vaccines and Related Biological Products Advisory Committee (VRBPAC). Cervarix human papillomavirus bivalent (types 16 and 18): briefing document [2009 Sep 9]; p64. In: US Food and Drug Administration [Internet]. Available from: http://www.fda.gov/downloads/Adviso...uctsAdvisoryCommittee/UCM181371.pdf.
   Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012 Jan; 13(1):89-99; Epub 2011 Nov 8. Erratum in: Lancet Oncol 2012 Jan;13(1):e1. PMID: 22075171; http://dx.doi.org/10.1016/S1470-2045(11)70286-8
   PubMed Web of Science ®Google Scholar
• Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, Wacholder S, Ghosh A, Li Y, Lowy DR, et al. Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates. Am J Epidemiol 2014 Sep 15; 180(6):599-607; Epub 2014 Aug 19. PMID: 25139208; PubMed Central PMCID: PMC4157699; http://dx.doi.org/10.1093/aje/kwu168
   PubMed Web of Science ®Google Scholar
• Konno R, Yoshikawa H, Okutani M, Quint W, V Suryakiran P, Lin L, Struyf F. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women. Hum Vaccin Immunother 2014; 10(7):1781-94; PubMed Central PMCID: PMC4186043; PMID:25424783; http://dx.doi.org/10.4161/hv.28712
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009 Dec 12; 374(9706):1975-85; PMID: 19962185; http://dx.doi.org/10.1016/S0140-6736(09)61567-1
   PubMed Web of Science ®Google Scholar
• Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010 Mar 3; 102(5):325-39; PMID: 20139221; http://dx.doi.org/10.1093/jnci/djp534. Epub 2010 Feb 5.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Joura E, Iversen OE, Bautista O, Chen J, Moeller E, Ritter M, Luxembourg A. Efficacy of a novel 9-valent HPV L1 vaccine against disease irrespective of HPV type. In Proceedings of International Papillomavirus Society - 29th International Papillomavirus Conference: pg. 252 [Abstract PH.PD04.05]. Seattle, WA: 2014 Aug 21–25.
   Google Scholar
• Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev 2014 Oct;23(10):1997-2008; PMID: 25274978; http://dx.doi.org/10.1158/1055-9965.EPI-14-0410
   PubMed Web of Science ®Google Scholar
• Pinto LA, Viscidi R, Harro CD, Kemp TJ, García-Piñeres AJ, Trivett M, Demuth F, Lowy DR, Schiller JT, Berzofsky JA, et al. Cellular immune responses to HPV-18, −31, and −53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006 Sep 30; 353(2):451-62. Epub 2006 Jul 24; http://dx.doi.org/10.1016/j.virol.2006.06.021
   PubMed Web of Science ®Google Scholar
• Boxus M, Lockman L, Fochesato M, Lorin C, Thomas F, Giannini SL. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine 2014 May 30; 32(26):3232-6; Epub 2014 Apr 13; http://dx.doi.org/10.1016/j.vaccine.2014.04.005
   PubMed Web of Science ®Google Scholar